Covered recipient · General Payments record
TERRY M JONES
Allopathic & Osteopathic Physicians Dermatology
General Payments · PY2018–2024
$3,133.09
- Reported across 195 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $305.77 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $75.60 | 4 |
| Janssen Biotech, Inc. | $59.07 | 3 |
| ABBVIE INC. | $43.33 | 2 |
| E.R. Squibb & Sons, L.L.C. | $38.15 | 2 |
| GENZYME CORPORATION | $28.96 | 1 |
| UCB, Inc. | $27.65 | 2 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $16.66 | 1 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $16.35 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $19.92 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104009782 | CMS |
| ABBVIE INC. | $23.41 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104009784 | CMS |
| Amgen Inc. | $25.46 | 01/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117590837 | CMS |
| Amgen Inc. | $14.83 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117590839 | CMS |
| Amgen Inc. | $14.17 | 07/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117590841 | CMS |
| Amgen Inc. | $21.14 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117590843 | CMS |
| E.R. Squibb & Sons, L.L.C. | $21.18 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101840302 | CMS |
| E.R. Squibb & Sons, L.L.C. | $16.97 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101840336 | CMS |
| GENZYME CORPORATION | $28.96 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139583970 | CMS |
| Janssen Biotech, Inc. | $13.28 | 09/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078695849 | CMS |
| Janssen Biotech, Inc. | $25.88 | 10/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078695984 | CMS |
| Janssen Biotech, Inc. | $19.91 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078695924 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $16.35 | 04/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153817953 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $16.66 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152207536 | CMS |
| UCB, Inc. | $13.15 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143411981 | CMS |
| UCB, Inc. | $14.50 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143411986 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.